Viatris Agrees to Acquire Pacira BioSciences for $1.65 Billion in Non-Opioid Pain Therapy Expansion

Viatris (VTRS) will acquire Pacira BioSciences (PCRX) for $1.65B ($36.50 per share), adding two pain therapies to its portfolio. Pacira generated $746M revenue and $177M EBITDA in the last 12 months. The deal is expected to close by the end of 2026 and be immediately accretive to Viatris' financials.

Original reporting
Published Oct 8, 2026, 2:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 3:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Viatris Agrees to Acquire Pacira BioSciences for $1.65 Billion in Non-Opioid Pain Therapy Expansion — source image
Decision brief

The 30-second read

$VTRSBullishHigh
01

Why it matters

The deal is positioned as immediately accretive, adding $746 M revenue and $177 M EBITDA, funded largely by cash, with minimal leverage impact.

02

Market read

The acquisition creates a larger non‑opioid portfolio for Viatris, likely moving both stocks on the announcement.

03

What to watch

Potential regulatory scrutiny of the tender offer and the need for Pacira shareholders to tender enough shares for deal closure.

Relevance 9/10Novelty 9/10Timing: today

Background

Viatris seeks to expand its specialty medicines business through the acquisition of Pacira's established non‑opioid pain therapies.

Company-level read

Ticker impact

$VTRSBullishHigh confidence
Context

Viatris announced a $1.65 B cash acquisition of Pacira, offering $36.50 per share, which is expected to be immediately accretive to its guidance.

Expected impact

upward pressure as the market prices in the immediate earnings accretion and expanded product portfolio

Evidence & confidence

The deal adds $746 M of revenue and $177 M of adjusted EBITDA, funded mostly with excess cash, and is expected to close by year‑end.

$PCRXBearishHigh confidence
Context

Pacira BioSciences agreed to be acquired for $36.50 per share in cash, ending its independent trading on Nasdaq.

Expected impact

downward pressure as the market aligns the stock with the $36.50 cash offer

Evidence & confidence

The transaction will delist Pacira; cash consideration sets a clear floor, prompting a sell‑off to the offer price.

Market effects

Strengthens the specialty pharma and non‑opioid pain‑management segment, potentially prompting peers to reassess pipelines.

U.S. market focus; limited immediate effect on international markets beyond Viatris' global footprint.

Adds a sizable non‑opioid portfolio to a global generic leader, modestly influencing worldwide pharma M&A sentiment.

Counterpoint

If integration costs exceed expectations, the accretion could be overstated, weighing on Viatris.

Key entities

  • Viatris

    NASDAQ‑listed generic and specialty pharma company acquiring Pacira.

  • Pacira BioSciences

    NASDAQ‑listed developer of non‑opioid pain treatments being acquired.

Related articles

$VTRSMedAI 8/10

Viatris completes $1.6B acquisition

Viatris Inc. (VTRS) completed its $1.65B acquisition of Pacira BioSciences Inc. (PCRX), a developer of nonopioid pain treatments. The deal aims to strengthen Viatris's U.S. innovative medicines business and establish leadership in non-opioid pain management, according to the company.

$VTRSMedAI 8/10

Viatris Completes Acquisition of Pacira BioSciences for $36.50 Per Share, Expanding Non-Opioid Pain Management Portfolio

Viatris (VTRS) completed its acquisition of Pacira BioSciences (PCRX) for $36.50 per share, expanding its non-opioid pain management portfolio. Pacira is expected to contribute $90M-$100M in revenue for the remainder of 2026. The deal strengthens Viatris' U.S. innovative medicines business and positions it in the non-opioid pain management market.

$VTRSMedAI 9/10

Viatris Closes $1.65 Billion Pacira Deal for Non-Opioid Pain Medicines

Viatris (VTRS) completed its $1.65 billion acquisition of Pacira BioSciences (PCRX) at $36.50 per share. The deal adds two pain treatments, EXPAREL and ZILRETTA, with expected revenue of $90M-$100M for the rest of 2026. Pacira reported $746M in revenue and $177M in adjusted EBITDA for the year ending June 2026. Viatris plans to expand the products' reach and advance Pacira's clinical-stage assets.